CA
REGN icon

Claro Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Claro Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Sell
502
-66
-12% -$44.9K 0.03% 393
2026
Q1 		$439K Buy
568
+11
+2% +$8.42K 0.05% 271
2025
Q4 		$430K Buy
557
+102
+22% +$69.3K 0.06% 255
2025
Q3 		$256K Buy
+455
New +$257K 0.04% 342
2025
Q2 		– Sell
-620
Closed -$393K – 481
2025
Q1 		$393K Buy
620
+217
+54% +$149K 0.05% 321
2024
Q4 		$287K Sell
403
-75
-16% -$62.9K 0.04% 371
2024
Q3 		$502K Buy
478
+251
+111% +$279K 0.06% 266
2024
Q2 		$239K Buy
+227
New +$220K 0.04% 368
2019
Q1 		– Sell
-2
Closed -$1K – 762
2018
Q4 		$1K Buy
+2
New +$732 ﹤0.01% 1055

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Claro Advisors's REGN Position: Q2 2026 in Review

Claro Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $44.9K and leaving 502 shares worth $313K. The position accounts for 0.03% of the portfolio, ranked #393.

Claro Advisors first reported a position in REGN in Q4 2018 and has held it in 9 quarters since. The position peaked at $502K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Claro Advisors held 502 shares of Regeneron Pharmaceuticals worth $313K as of Q2 2026.
  • Claro Advisors sold 66 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $44.9K.
  • Regeneron Pharmaceuticals made up 0.03% of Claro Advisors's portfolio in Q2 2026, its #393 holding.
  • Claro Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
  • Claro Advisors's Regeneron Pharmaceuticals position peaked at $502K in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Claro Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.